STAT+: Will Novo Nordisk’s slashing of obesity drug prices save patients’ money? It depends
Will Novo Nordisk’s slashing of obesity drug prices save patients’ money or expand access? It depends.
Medical News
STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments
Comments opposing Medicare's efforts to lower U.S. drug prices provide a roadmap to potential legal challenges ahead.
STAT+: Novo reports ‘triple G’ obesity drug study results
Fresh off a failed trial that sent its shares plummeting, Novo Nordisk said that one of its experimental obesity drugs helped patients lose nearly 20% of their weight after 24 weeks…
Novo to knock down Ozempic, Wegovy list prices next year, but self-pay channels unaffected
Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price.
AstraZeneca CEO pay hits $23.9M amid ‘significant geopolitical uncertainty’ in 2025
AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty” to advance the British pharma toward an ambitious 2030 goal.
BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder
Just three months after further scaling back its support for the struggling hemophilia A gene therapy Roctavian, the company is walking away altogether by pulling the treatment from the market.
Alzheimer’s may begin with a silent drop in brain blood flow
Subtle changes in brain blood flow and oxygen use are closely linked to hallmark signs of Alzheimer’s, including amyloid plaques and memory-related brain shrinkage. Simple, noninvasive scans may one day help spot risk earlier—by looking at the brain’s vascular health, not just its plaques.
Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind's approved GLP-1 in China
Looking to gain an edge as its broader obesity ambitions take shape, Pfizer has picked up the rights to a recently approved GLP-1 in China, unlocking an immediate commercial opportunity in type 2 diabetes, with the potential for a weight loss nod not far behind.
Novartis settles 18-month-old lawsuit from estate of Baltimore woman whose cells were extracted 75 years ago
The family of a Baltimore woman whose cells were extracted for medical research without her consent 75 years ago has settled a lawsuit with Novartis, with terms of the agreement confidential. Lawsuits the estate has filed against Ultragenyx and Viatris remain active.
STAT+: New treatment approach could give IBD patients hope, and be a bonanza for drugmakers
New treatment approaches could give inflammatory bowel disease patients hope, and make drugmakers a bonanza.
STAT+: Jeffrey Epstein’s tissue samples ignited a furor in the Harvard lab of George Church
Exclusive: Harvard geneticist George Church knew more about Jeffrey Epstein's activities than he has previously said, before accepting new donations from the sex offender.
STAT+: Digital twins, the holy grail of preventative health, are still only a ‘Frankensteinian proof of principle’
AI advances and new data on genomics, patient outcomes, and drug performance have pushed the idea of “digital twins” closer to reality than ever before.
Indivior picks Havas to lead US marketing efforts as DTC push ramps up
Havas will lead Indivior’s integrated strategy, creative, media and digital efforts across healthcare professional and direct-to-consumer audiences.
Scientists engineer bacteria to eat cancer tumors from the inside out
Researchers are engineering bacteria to invade tumors and consume them from the inside. Because tumor cores lack oxygen, they’re the perfect breeding ground for these microbes. The team added a genetic tweak that helps the bacteria survive longer near oxygen-exposed edges — but only once enough of them are present to trigger the change. It’s a carefully programmed biological attack that could one
Massive US study finds higher cancer death rates near nuclear power plants
A sweeping nationwide study has found that U.S. counties located closer to operating nuclear power plants have higher cancer death rates than those farther away. Researchers analyzed data from every nuclear facility and all U.S. counties between 2000 and 2018, adjusting for income, education, smoking, obesity, environmental conditions, and access to health care. Even after accounting for those fac
Training harder could be rewiring your gut bacteria
Training harder may do more than build muscle—it could transform your gut. Researchers found that intense workouts change the balance of bacteria and important compounds in athletes’ digestive systems. When training loads dropped, diet quality slipped and digestion slowed, triggering different microbial shifts. These hidden changes might influence performance in ways scientists are only beginning
STAT+: Bayer sues J&J over ‘false and misleading claims’ about competing prostate cancer treatments
Bayer sued rival Johnson & Johnson for launching a “false advertising campaign” based on flawed data to wrongfully promote its drug as more effective.
STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications
The FDA expects a flood of applications for a new "plausible mechanism pathway" for approval of bespoke gene-editing treatments.
STAT+: Medicare’s AI ‘modernization’ project, and the Ohio hospital antitrust battle
Would you trust AI to help you pick your Medicare plan?
AbbVie advances US expansion with $380M for 2 new North Chicago API plants
The new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company's plan to infuse $100 billion into its American operations over the next decade.